CIK 0001785279 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Metagenomi Therapeutics, Inc.
Sign in to watch- Ticker
- MGX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 813909017
- Phone
- (510) 871-4880
- Business address
- 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
- Former names
- Metagenomi, Inc., Metagenomi Technologies, LLC
- Open-market buys, last 90 days
- $23,401
- in 1 filing
- Open-market sales, last 90 days
- $5,107
- in 3 filings
Net +$18,294. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion | +1,770,888 | 1,770,888 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion | +1,180,592 | 2,951,480 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion | +589,662 | 3,541,142 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion | +509,855 | 4,050,997 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion · Series A-1 Convertible Preferred Stock | −3,093,580 | 0 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion · Series A-4 Convertible Preferred Stock | −2,062,387 | 0 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion · Series B Convertible Preferred Stock | −1,030,086 | 0 | ||
| 2024-02-13 | BAYER HEALTHCARE LLC 10% owner | Conversion · Series B-1 Convertible Preferred Stock | −890,671 | 0 | ||
| 2024-02-13 | Novo Holdings A/S 10% owner | Conversion | +839,175 | 939,175 | ||
| 2024-02-13 | Novo Holdings A/S 10% owner | Purchase | +800,000 | $15.00 | $12.0M | 1,739,175 |
| 2024-02-13 | Novo Holdings A/S 10% owner | Conversion · SERIES B PREFERRED STOCK | −147,415 | 0 | ||
| 2024-02-13 | Novo Holdings A/S 10% owner | Conversion · SERIES B-1 PREFERRED STOCK | −691,760 | 0 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion | +513,004 | 769,845 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion | +1,896,445 | 1,896,445 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion · Series A-2 Preferred Stock | −353,005 | 0 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion · Series A-3 Preferred Stock | −119,699 | 0 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion · Series A-4 Preferred Stock | −423,469 | 0 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion · Series A-4 Preferred Stock | −2,062,387 | 0 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion · Series B Preferred Stock | −1,143,905 | 0 | ||
| 2024-02-13 | Bernales Sebastian Director | Conversion · Series B-1 Preferred Stock | −106,627 | 0 |
Page 5 of 6 · 101 trades